Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › atorvastatin

atorvastatin

8 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of atorvastatin

124 trials tracked of atorvastatin: 61 in phase 3 or 4 and 18 with published results. The most-cited published study has 511 citations.

124Trials tracked
61Phase 3 & 4
0Recruiting
18With published results
Phase distribution
Phase 4 23 Phase 3 38 Phase 2 43 Phase 1 13 Other / NA 7
  1. Phase 3 Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3 Completed · 511 cited
  2. Phase 3 Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins Completed · 363 cited
  3. Phase 4 Self-Assessment Method for Statin Side-effects Or Nocebo Completed · 180 cited
  4. Phase 3 Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD Completed · 161 cited
  5. Phase 3 Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody Completed · 147 cited
  6. Phase 4 Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication Completed · 129 cited
Show 44 more trials
  1. Phase 4 Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling Completed · 97 cited
  2. Phase 4 Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia Completed · 86 cited
  3. Phase 3 Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia Completed · 49 cited
  4. Phase 3 An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia Completed · 39 cited
  5. Phase 3 Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia Completed · 32 cited
  6. Phase 3 An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia Completed · 31 cited
  7. Phase 3 Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin Completed · 22 cited
  8. Phase 4 Statin Therapy in Heart Failure: Potential Mechanisms of Benefit Completed · 21 cited
  9. Phase 3 Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439) Completed · 13 cited
  10. Phase 4 Study of the Effect of Atorvastatin for Reducing Aging-related Complication in HIV-infected Patients Older Than 45 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based Regimen Completed · 11 cited
  11. Phase 3 Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy Completed · 8 cited
  12. Phase 3 Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE) Completed · 2 cited
  13. Phase 4 Modulation of Monocyte Activation by Atorvastatin in HIV Infection Completed
  14. Phase 4 Efficacy and Safety Study of Pitavastatin Compared to atoRvastatin in Type 2 dIabeTes Mellitus With Hypercholesterolemia Completed
  15. Phase 4 Effect of Atorvastatin on Bone-vascular Axis Completed
  16. Phase 4 Statin Therapy for Ischemic and Nonischemic Cardiomyopathy Completed
  17. Phase 4 Systems Biological Assessment of Statin Effect on Vaccine Responses Completed
  18. Phase 4 The Use of Statins Following a Left Atrial Catheter Ablation Procedure to Prevent Atrial Fibrillation Completed
  19. Phase 4 Evaluation of the Efficacy and Safety of Rosuvastatin 5 mg Versus Pravastatin 40 mg and Atorvastatin 10 mg in Type IIa and IIb Hypercholesterolaemic Patients Completed
  20. Phase 4 Bioequivalence Study Comparing A New 10 Mg Atorvastatin Tablet To A 10 Mg Atorvastatin Commercial Tablet Completed
  21. Phase 4 Atorvastatin Pre-Treatment Study In Asian Patients With Acute Coronary Syndrome Completed
  22. Phase 4 Systemic Immunomodulatory Effects and Pharmacogenetics of Atorvastatin in Early Atherosclerosis Completed
  23. Phase 4 Bioequivalence Study Comparing A New 80 Mg Atorvastatin Tablet To A 80 Mg Atorvastatin Commercial Tablet Completed
  24. Phase 4 Evaluation of Ezetimibe and Atorvastatin Coadministration Versus Atorvastatin or Rosuvastatin Monotherapy in Japanese Patients With Hypercholesterolemia (Study P06027)(COMPLETED) Completed
  25. Phase 4 Lipitor Korean Atorvastatin Goal Achievement Across Risk Levels Study Completed
  26. Phase 4 Ezetimibe Plus (+) Simvastatin Versus Atorvastatin Comparative Study (0653A-092)(COMPLETED) Completed
  27. Phase 4 ROMEO (Rosuvastatin in Metabolic syndrOme) Completed
  28. Phase 4 Effects of Atorvastatin on Endothelial Progenitor Cells After Coronary Surgery Completed
  29. Phase 4 The Role of P-glycoprotein in Sitagliptin Clinical Pharmacology Completed
  30. Phase 3 Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia (P05456) Completed
  31. Phase 3 Atrovastatin for Preventing Atrial Fibrillation Following Open Cardiac Valve Repair Completed
  32. Phase 3 Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood Completed
  33. Phase 3 Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk Completed
  34. Phase 3 Atorvastatin Three Year Pediatric Study Completed
  35. Phase 3 Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood Completed
  36. Phase 3 Study Comparing Pitavastatin and Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia Completed
  37. Phase 3 Lipid Efficacy and Safety in Participants With Mixed Hyperlipidemia (MK-0524B-024) Completed
  38. Phase 3 A Study to Evaluate the Effectiveness of Ezetimibe/Atorvastatin 10 mg/20 mg Combination Tablet Compared to Marketed Ezetimibe 10 mg and Atorvastatin 20 mg Tablets in Participants With High Cholesterol (MK-0653C-185 AM1) Completed
  39. Phase 3 Statins in Children With Type 1 Diabetes and Hypercholesterolemia Completed
  40. Phase 3 LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2 Completed
  41. Phase 3 MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162) Completed
  42. Phase 3 Study to Compare the Efficacy of Pitavastatin With That of Atorvastatin in Lowering Cholesterol Levels Completed
  43. Phase 3 Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112) Completed
  44. Phase 3 CRESTOR Athero Imaging Head to Head IVUS Study Completed

Showing the 50 most-cited and recently-updated of 124 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Pantoprazole exposure linked to insulin autoimmune syndrome in case report
Diabetes & Endocrinology Sys. Review
Pantoprazole exposure linked to insulin autoimmune syndrome in case report Stopping a stomach acid drug helped a patient with low blood sugar recover
This case report describes a patient with insulin autoimmune syndrome (IAS) temporally associated with pantoprazole exposure. Discontinuatio…
A patient with insulin autoimmune syndrome found relief when doctors stopped a common stomach acid medication, suggesting a possible link be…
Frontiers Jun 3, 2026
Cerivastatin best for total cholesterol, simvastatin for LDL-C in DKD with hyperlipidemia
Diabetes & Endocrinology Meta-analysis
Cerivastatin best for total cholesterol, simvastatin for LDL-C in DKD with hyperlipidemia Lipid-Lowering Drugs Show Different Benefits for Kidney Disease
A network meta-analysis of 20 RCTs in patients with diabetic kidney disease and hyperlipidemia found that cerivastatin most effectively redu…
A review of 20 trials found that different statins and fenofibrate have unique effects on cholesterol, kidney markers, and heart risks in di…
Frontiers May 29, 2026
Review highlights lack of comprehensive evaluation for atorvastatin anticancer mechanisms and therapeutic potential
Oncology Sys. Review
Review highlights lack of comprehensive evaluation for atorvastatin anticancer mechanisms and therapeutic potential Review finds lack of research on atorvastatin's anticancer potential
This narrative review discusses the potential anticancer mechanisms and therapeutic potential of atorvastatin.
A review notes that a comprehensive evaluation of atorvastatin's anticancer mechanisms and potential is currently lacking.
Frontiers Apr 25, 2026
Atorvastatin dose and PCI timing predict hypoperfusion in STEMI patients
Cardiology Cohort
Atorvastatin dose and PCI timing predict hypoperfusion in STEMI patients New Tool Predicts Heart Damage Risk After Emergency Stent Procedure
This cohort study evaluated 434 patients with acute ST-segment elevation myocardial infarction (STEMI) who underwent primary PCI.
This new tool could help doctors identify high-risk heart attack patients sooner, potentially improving survival and recovery rates.
Frontiers Apr 21, 2026
Intensive medical treatment failed to reduce major adverse cardiovascular events in women with suspected ANOCA/INOCA over 2.5 years
Cardiology RCT
Intensive medical treatment failed to reduce major adverse cardiovascular events in women with suspected ANOCA/INOCA over 2.5 years Intensive heart medication did not reduce major events in women with suspected ANOCA
This randomized controlled trial enrolled 2,476 women with suspected ANOCA/INOCA across 71 US sites.
Intensive heart medication did not reduce major events in women with suspected ANOCA, finding that aggressive treatment offered no benefit o…
Apr 6, 2026
High-dose atorvastatin reduces contrast-induced acute kidney injury after coronary angiography in Egyptian patients
Radiology & Imaging RCT
High-dose atorvastatin reduces contrast-induced acute kidney injury after coronary angiography in Egyptian patients Can a common cholesterol drug protect kidneys during heart imaging?
A randomized controlled trial of 120 Egyptian patients undergoing elective coronary angiography found that adding high-dose atorvastatin (80…
A common cholesterol drug cut kidney injury risk in half compared to fluids alone during heart imaging tests.
Apr 3, 2026
Very high-intensity statin with ezetimibe lowers LDL-C more than high-intensity regimen after AMI
Cardiology RCT
Very high-intensity statin with ezetimibe lowers LDL-C more than high-intensity regimen after AMI Can a stronger statin dose after a heart attack lower cholesterol more?
A single-center RCT of 220 AMI patients compared very high-intensity vs.
A stronger statin dose after a heart attack lowers bad cholesterol better but causes more side effects, forcing some patients to cut back on…
Apr 3, 2026
Atorvastatin evaluated for dyslipidemia in children with steroid-sensitive nephrotic syndrome
Nephrology Phase IV
Atorvastatin evaluated for dyslipidemia in children with steroid-sensitive nephrotic syndrome Can a common cholesterol drug protect children's hearts and kidneys from a hidden danger?
A quasi-experimental study of 100 children aged 8-18 years with steroid-sensitive nephrotic syndrome and dyslipidemia evaluated the effectiv…
A common cholesterol drug called atorvastatin may help children with kidney disease reach safer heart and blood fat levels when diet alone i…
CT.gov Mar 30, 2026